Metformin reduces the risk of CRC [113], reducing serum inflammatory factors[103], and inhibits tumor growth through the AMPK/mTOR pathway, mTOR/AKT pathway, and LKB1/AMPK pathway, thus facilitating the prognosis of patients [114–116]. This evidence concerns the gene MTOR and colorectal carcinoma.